Search

Your search keyword '"Canellas, Anthony"' showing total 10 results
Start Over Author "Canellas, Anthony" Search Limiters Peer Reviewed
10 results on '"Canellas, Anthony"'

1. Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study

Author

Falchero, Lionel, Guisier, Florian, Darrason, Marie, Boyer, Arnaud, Dayen, Charles, Cousin, Sophie, Merle, Patrick, Lamy, Régine, Madroszyk, Anne, Otto, Josiane, Tomasini, Pascale, Assoun, Sandra, Canellas, Anthony, Gervais, Radj, Hureaux, José, Le Treut, Jacques, Leleu, Olivier, Naltet, Charles, Tiercin, Marie, Van Hulst, Sylvie, Missy, Pascale, Morin, Franck, Westeel, Virginie, and Girard, Nicolas

Published
2023
Full Text
View/download PDF

2. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Author

Moulin, Solenne, Leleu, Olivier, Leparree, Sylvie, Goasdoue, Henri, Piprot, Christine, Tourneur, Gerald, Bayart, Vincent, Lignier, Delphine, Lachaier, Emma, Khamari, Marwa, Coutte, Alexandre, Siembida, Nicolas, Houessinon, Aline, Regimbeau, Jean Marc, Chauffert, Bruno, Moreira, Aurélie, Hautefeuille, Vincent, Hee, Christine, Boone, Mathieu, Bihan, Céline, Chive, Emilie, Poulet-Potriquier, Stéphane, Fahem, Rachida, Luet, Dominique, Roquin, Guillaume, Vitellius, Carole, Cornet-Trichereau, Nathanaëlle, Caroli-Bosc, François-Xavier, Thirot-Bidault, Anne, Ropert, Stanislas, Gachet - Masson, Julie, Dehais, Mélanie, L'helgoualc'h, Gwen-Ael, Ali-Mahamadou, Ibrahim, Talfi, Safia, Belmont, Laure, Kilendo, Dieudonné, Benrezzak, Nasro, Dubief, Emeline, Conroy, Guillaume, Delique, Laurence, Basso, Maud, Pons, Isabelle, Salignon, Karine, Villing, Anne-Laure, Mougenot, Emmanuelle, Porebski, Cassandra, Guiatni, Asma, Cloarec, Nicolas, Mineur, Laurent, Bouchaud, Marie, David, Céleste, Peytier, Annie, Greletty, Thomas, Audemar, Franck, Vignes, Emanuelle, Minne, Floriane, Goldzak, Guillaume, Huysman, Fabienne, Hocine, Fayçal, Lakkis, Zaher, Mansi, Laura, Meynard, Guillaume, Almotlak, Hamadi, Klajer, Elodie, Sun, Xu-Shan, Wasselin, Julie, Catala, Pascale, Mazuy, Claire, Vandamme, Hélène, Prevost, Jean-Briac, Fadin, Aurélie, Basson, Laurent, Huguet, Jean-Baptiste, Dos Santos, Emmanuelle, Jany, Bérangère, Saad, Alain, Goutorbe, Frédéric, Oziol, Eric, Ramdani, Mohamed, Kadiri, Ouafae, Garbay, Delphine, Huet, Clotilde, Giroux Leprieur, Etienne, Teng, Wen, Monvoisin, Justine, Arnaud Coffin, Patrick, Roux, Sylvie, Orfeuvre, Hubert, Chagros, Mélanie, Pillon, Didier, Rassoul, Agathe, Poureau, Pierre Guillaume, Novello, Cécile, Ducray, François, Trouba, Cécile, Bastit, Vianney, Babin, Emmanuel, Thariat, Juliette, Leon, Vincent, Courtecuisse, Anne-Catherine, Vambre, Julie, Tack, Vincent, Desauw, Christophe, Meniai, Fatima, Peres, Christina, Esparcieux, Aurélie, Perrier, Hervé, Doux, Nathalie, Kaphan, Régis, Roques, Bertrand, Rebischung, Christine, Mille, Dominique, Fernandes, Gaëlle, Abdelli, Naceur, Jousset, Natacha, Combe, Pierre, Jonveaux, Eric, Dumont, Patrick, Kanaan, Marc, Berthelot Gras, Corinne, Panis, Valérie, Kaluzinski, Laure, Venant-Valery, Marjolène, Lam, You-Heng, Vallee, Laura, Riviere, Frédéric, Durand, Muriel, Benghadid, Dihya, Villeneuve, Emilie, Hentic Dhome, Olivia, Laurent, Lucie, Bounouar, Zedjiga, De Mestier, Louis, Dubois, Jacqueline, Eyriey, Magali, Moreau, Lionel, Ahle, Guido, Baihas, Dib, Aldabbagh, Kaïs, Degriffolet, Dominique, Sebbagh, Virginie, Seghezzi, Jean-Christophe, Lozach-Brugirard, Marion, Mandrou, Julie, Mavier, Loubna, Hennetier, Florence, Wagner, Jean-Philippe, Carola, Elisabeth, Chandirakumaran, Karthiga, Loutski, Sandrine, Cojean-Zelek, Isabelle, Bouras, Amina, Lacour, Sandrine, Froura, Fahem, Ben Nadji, Hadjer, Cattelain, Sophie, Darloy, Franck, Jolimoy Boilleau, Geneviève, Maissiat, Cyrielle, Darut-Jouve, Ariane, Lorgis, Véronique, Charifi-Alaoui, Ikram, Ghiringhelli, François, Drouillard, Antoine, Chaix, Marie, Manfredi, Sylvain, Lepage, Côme, Gagnaire, Alice, Latournerie, Marianne, jourdan, Sofia, Perrot, Nora, folia, Mireille, Minello, Anne, Jouve, Jean-Louis, Fery, Marielle, Landau, Alain, Evrard, Diane, Valenza, Bruno, Paitel, Jean-François, Chablais, Laetitia, Kreitmann, Thomas, Lancry-Lecomte, Laurence, Monard, Adrien, Faugeras, Eve, Boucheret, Paul, Glommeau, Cécile, Tchikladze, Christine, Garnier Tixidre, Claire, Long, Jérôme, Zaidi, Manel, Delabarre, Véronique, Meyzenc, Juliette, Ferrand, Loïc, Moro-Sibilot, Denis, Bouheret, Paul, Leyronnas, Cécile, Herve, Camille, Thoor, Audrey, Jacquet, Emanuelle, Roth, Gaël, Madapathage-Senanyake, Videsheka, Chupeau, Peggy, Bieber, Elsa, Rosso, Maud, Lepage, Isabelle, Priou, Frank, Laly, Margot, Aprelon, Sylvie, Sobolak, Natacha, Homokos, Helen, Pointreau, Yoann, Watelle, Fabienne, Pham-Becker, Alice, Lauridant, Géraldine, Turpin, Anthony, Dujardin, Charlotte, Lenglin, Etienne, Nienguet Tsota, Aimée, Dominguez, Sophie, Forestier, Alexandra, Nouvel, Franck, Lerooy, Justine, Ratajczak, Céline, Romano, Olivier, Brzyski, Dorothéee, Barriere, Aurélien, Genet, Dominique, Tisse, Julien, Zasadny, Xavier, Grelet, Adeline, Hennion-Imbault, Amélie, Haustraete, Eglantine, Louafi, Samy, Awad, Manal, Zekri, Younes, Cheneau, Caroline, Leissen, Nolwen, Egreteau, Joëlle, Breant, Alexandra, Sarabi, Matthieu, Labonne, Stéphanie, Forestier, Julien, Leclercq, Céline, Prunier-Bossion, Florence, Ray Coquard, Isabelle, Guillet, Marielle, Theillaumas, Aurélie, Prome, Emilie, Walter, Thomas, Philouze, Pierre, Lawo, Melody, De Talhouet, Solène, Beuvelot, Johanne, Molin, Yann, Bellecoste Martin, Marie, Saussereau, Maud, Agnelli, Lauren, Fakhry, Nicolas, Laplace, Christophe, Norguet Monnereau, Emmanuelle, Boucard, Céline, Djenad, Kahina, Fontaine, Catherine, Seitz, Jean-François, Dahan, Laétitia, Sigrand, Julie, Duluc, Muriel, Locher, Christophe, Fleury, Marjory, Brou Marie, Ange, Berkane, Ramdane, Poupblanc, Séverine, Auby, Dominique, Petran, Daniela, Texereau, Patrick, Guerineau, Elodie, Andre, Morgan, Mahjoubi, Linda, Sarrazin, Fanny, Jeanson, Sonia, Gschwend, Anthony, Birr, Virginie, Debieuvre, Didier, Fore, Mathieu, Noirclerc, Monique, Dahou, Sihem, Spaeth, Dominique, Lambotin, Mélanie, Lelu, Thomas, Linot, Benjamin, Hugon, Nathalie, Rousseau, Dominique, Castanie, Hélène, Lenne, Carole, Lortholary, Alain, Cessot, Anatole, Merzoug, Messaouda, Naudin, Cécile, Vannetzel, Jean-Michel, Aziz, Ghina, Hadj Arab, Yacine, Pernes, Stéphanie, Roche-Lachaise, Isabelle, Fiteni, Frédéric, Yahiaoui, Hadjer, Marel Lopez, Gwendoline, Oddoz, Jeanne, Peira, Fabienne, Michel, Olivier, Meunier, Jérôme, Ouahrani, Brahim, Roger, Antoine, Branco, Sonia, Nguyen, Van, Gisselbrecht, Mathilde, Hammad, Ghania, Mordant, Pierre, Stroksztejn, Magda, Pocard, Marc, Nlo Meyengue, Luc, Aparicio, Thomas, Sacco, Emmanuelle, Simon Anne, Sophie, Fabre-Guillevin, Elizabeth, Wislez, Marie, Slim, Marine, Zaanan, Aziz, Cadranel, Jacques, Pluvy, Johan, Ursu, Rénata, Geraldo, Amyrath, Lihi, Rime, Vo, Maryline, Brouk, Zohra, Colle, Raphaël, Bennamoun, Mostefa, Lacan, Fabrice, Louvet, Christophe, Mebarki, Soraya, Veyri, Marianne, Paillaud, Elena, Lucas, Christelle, Dubreuil, Olivier, Lyamani, Jamila, Idbaih, Ahmed, Agguini, Hanane, Soularue, Emilie, Canellas, Anthony, Zalcman, Gérard, Jourdaine, Clément, Verillaud, Benjamin, Herzine, Hakima, Raymond, Eric, Mathiot, Nathalie, Palmieri, Lola Jade, Epanya, Christian, Taieb, Julien, Bertrand, Eliane, Goujon, Gaël, Namour, Céline, Gazeau, Benoit, Zafirova, Biljana, Mirghani, Haitham, Belin, Catherine, Belkhir, Kahina, Gharib, Myriam, Vozy, Aurore, Amrane, Karim, Spano, Jean-Philippe, Wassermann, Johanna, Feuvret, Loic, Bachet, Jean-Baptiste, Philonenko, Sara, Guillot, Laetitia, Zabbe, Marion, Gibiat, Stéphanie, Baylot, Camille, Jouinot, Aude, Leduc, Nicolas, Vieillot, Sabine, James, Laurie, Ducerf, Camille, Blanc, Jean-Frédéric, Falandry Leger, Claire, Wautot, Virginie, Chauvenet, Marion, Vincent, Aude, Tougeron, David, Goulvent, Sandrine, Suc, Etienne, Laurenty, Anne-Pascale, Marquis, Eric, Bonnaire, Margaux, Dewolf, Maxime, Brenet, Esteban, Billard, Delphine, Litre, Claude-Fabien, Dumazet, Antoine, Botsen, Damien, Vazel, Marion, Carlier, Claire, Bonnerave, David, Marchand-Crety, Charles, Bouche, Olivier, Fosse, Patricia, Sefrioui, David, Michel, Pierre, Watson, Sarah, Neuzillet, Cindy, Torche, Fatah, Muron, Thierry, Natur, Stéphane, Desgrippes, Romain, Bihel, Véronique, Ferrand, François-Régis, Leiterer, Caroline, Lavole, Julie, Moquet, Claire, Pressoir, Nathalie, Dziukala, Catherine, Ligeza Poisson, Catherine, Naji, Abdelhalim, Williet, Nicolas, Phelip, Jean-Marc, Di Palma, Fabrice, Kherrour Mehdi, Amina, Langrand-Escure, Julien, Fournel, Pierre, Pigne, Grégoire, Saban-Roche, Léa, Magne, Nicolas, Vassal, Cécile, Jacquin, Jean-Philippe, Ramirez, Carole, Vallard, Alexis, Collard, Olivier, Rivoirard, Romain, Graber, Ivan, Trager Maury, Stéphanie, Duboisset, Elodie, Ayllon Ugarte, Jorge, Rami, Dalilia, Saler, Christine, Reinbolt, Manon, Le Fevre, Clara, Ben Abdelghani, Meher, Dourthe, Louis-Marie, Perruisseau-Carrier, Joffrey, Nguimpi-Tambou, Marlène, Barret, Flavie, Di Stefano Anna, Luisa, Balthazard, Annie, Mabro, May, Vassord-Dang, Camille, Le Marchand, Mathilde, Vergniol, Julien, Pripon, Iulia, Daemaegdt, Axelle, Latry, Vanessa, Larrieu, Muna, Landry, Gaëlle, Touihri Maximin, Laetitia, Del Piano, Francesco, Barlet, Agnès, Vernisse, Mylène, Lafond, Sophie, Genin, Charline, Sibertin-Blanc, Camille, Chabrillac, Emilien, Gregoire, Caroline, Vergez, Sébastien, Panouille, Quentin, Guimbaud, Rosine, Richa, Floriane, Lebellec, Loïc, Gounin, Sophie, Buiret, Guillaume, Baudin, Marine, Hamon, Hervé, Deshorgue, Anne-Claire, Barrascout, Eduardo, Legrand, Stéphanie, Houlze, Morgane, Cambula, Linda, Lopez, Anthony, Fouquet, Guillaume, Touabi, Kahina, GermaIn, Adeline, Godbert, Benoit, Voivret, Florence, Perrin, Julie, Da Silva, Rosa, Bernichon, Emilie, Lièvre, Astrid, Ray-Coquard, Isabelle, Le Malicot, Karine, Paoletti, Xavier, Bouché, Olivier, Aldabbagh, Kais, Colle, Raphael, Hardy-Bessard, Anne-Claire, Colomba, Emeline, Bourhis, Jean, Gorphe, Philippe, Ursu, Renata, and Di Stefano, Anna Luisa

Published
2020
Full Text
View/download PDF

3. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients

Author

Gobbini, Elisa, Toffart, Anne Claire, Pérol, Maurice, Assié, Jean-Baptiste, Duruisseaux, Michaël, Coupez, Dahna, Dubos, Catherine, Westeel, Virginie, Delaunay, Myriam, Guisier, Florian, Veillon, Rémi, Gounant, Valérie, Giroux Leprieur, Etienne, Vanel, François-Roger, Chaabane, Nouha, Dansin, Eric, Babey, Hélène, Decroisette, Chantal, Barlesi, Fabrice, Daniel, Catherine, Fournel, Pierre, Mezquita, Laura, Oulkhouir, Youssef, Canellas, Anthony, Duchemann, Boris, Molinier, Olivier, Alcazer, Vincent, Moro-Sibilot, Denis, and Levra, Matteo Giaj

Published
2020
Full Text
View/download PDF

6. Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study.

Author

Ezzedine, Rémy, Canellas, Anthony, Naltet, Charles, Wislez, Marie, Azarian, Reza, Seferian, Andrei, and Giroux Leprieur, Etienne

Subjects
*THERAPEUTIC use of antineoplastic agents, *RESEARCH, *LIVER tumors, *SMALL cell carcinoma, *CANCER chemotherapy, *LUNG tumors, *METASTASIS, *CASE-control method, *TREATMENT effectiveness, *COMPARATIVE studies, *BRAIN tumors, *DESCRIPTIVE statistics, *SYMPTOMS, *IMMUNOTHERAPY, *EVALUATION
Abstract

Simple Summary: Chemoimmunotherapy (CT-IO) is the standard first-line treatment of advanced small cell lung cancer (SCLC). However, very limited efficacy data from real-life use of this combination are available. Moreover, patients included in pivotal phase III trials were highly selected. We conducted a retrospective multicentric (six academic centers) case–control study (n = 153), comparing two cohorts of patients who received first-line treatment, one treated with chemotherapy alone (between January 2017 and December 2018) and one with CT-IO (between January 2019 and December 2020), for an advanced SCLC. CT-IO confirmed its superiority compared to chemo alone. Interestingly, we showed that CT-IO was efficient in patients with brain and liver metastases. However, patients ≥70 years old and with a PS ≥2 did not benefit from CT-IO. This real-life study in one of the largest published to our knowledge on first-line CT-IO for advanced SCLC, with a large focus on specific populations (brain mets, elderly, and impaired PS). The current first-line standard treatment for advanced small cell lung cancer (SCLC) is a combination of chemotherapy and immunotherapy. However, few efficacy data are available in a real-life settings, including frail patients. The aim of this study is to describe the real-life efficacy of chemoimmunotherapy in an unselected SCLC population. We conducted a retrospective multicenter study, which compared two cohorts of patients with treatment-naive metastatic SCLC treated in six academic centers in the Greater Paris area. Cohort 1 included patients treated with chemotherapy between January 2017 and December 2018, and cohort 2 included patients treated with chemoimmunotherapy between January 2019 and December 2020. A total of 153 consecutive patients were included (cohort 1: n = 96; cohort 2: n = 57). Clinical characteristics were similar between the two cohorts. Overall survival (OS) was statistically higher in cohort 2 (median survival 15.47 months) than in cohort 1 (median survival 9.5 months) (p = 0.0001). OS for patients with a performance status ≥2 and for patients ≥70 years old was not statistically different between the two cohorts. Chemoimmunotherapy efficacy was better compared to chemotherapy alone in case of brain or liver metastases. In conclusion, the combination of chemoimmunotherapy in metastatic SCLC appears to provide a real-life OS benefit. Dedicated clinical trials are needed to test this strategy in patients with impaired performance status or advanced age. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.

Author

Assié, Jean-Baptiste, Crépin, Florian, Grolleau, Emmanuel, Canellas, Anthony, Geier, Margaux, Grébert-Manuardi, Aude, Akkache, Nabila, Renault, Aldo, Hauss, Pierre-Alexandre, Sabatini, Marielle, Bonnefoy, Valentine, Cortot, Alexis, Wislez, Marie, Gauvain, Clément, Chouaïd, Christos, Scherpereel, Arnaud, and Monnet, Isabelle

Subjects
DRUG efficacy, MESOTHELIOMA, RESEARCH, STATISTICS, CONFIDENCE intervals, MULTIVARIATE analysis, RETROSPECTIVE studies, NIVOLUMAB, PLEURAL tumors, DESCRIPTIVE statistics, EVALUATION
Abstract

Simple Summary: Immune-checkpoint inhibitors have only been studied in clinical trials for second-line and now first-line malignant pleural mesothelioma. Sometimes, results found in clinical trials do not translate to real-life settings. We aim to study second-line and onward nivolumab in malignant pleural mesothelioma to verify its effectiveness in France. We enrolled 109 patients from 11 centers in France. Our study proves in multivariate analysis that nivolumab has an efficacy against MPM. An intermediate LIPI score seems predictive of good response, but less in those < 70 years and for the first time in biphasic subtype. Ancillary studies are needed to more deeply explore these findings. Backgrounds: Malignant pleural mesothelioma (MPM) is a cancer with poor prognosis. Second-line and onward therapy has many options, including immune-checkpoint inhibitors with demonstrated efficacy: 10–25% objective response rate (ORR) and 40–70% disease-control rate (DCR) in clinical trials on selected patients. This study evaluated real-life 2L+ nivolumab efficacy in MPM patients and looked for factors predictive of response. Methods: This retrospective study included (September 2017–July 2021) all MPM patients managed in 11 French centers. Results: The 109 enrolled patients' characteristics were: median age: 69 years; 67.9% men; 82.6% epithelioid subtype. Strictly, second-line nivolumab was given to 51.4%. Median PFS and OS were 3.8 (3.2–5.9) and 12.8 (9.2–16.4) months. ORR was 17/109 (15.6%); 34/109 patients had a stabilized disease (DCR 46.8%). Univariable analysis identified several parameters as significantly (p < 0.05) prognostic of OS [HR (95% CI)]: biphasic subtype: 3.3 (1.52–7.0), intermediate Lung Immune Prognostic Index score: 0.46 (0.22–0.99), progression on the line preceding nivolumab: 2.1 (1.11–3.9) and age > 70 years: 2.5 (1.5–4.0). Multivariable analyses retained only biphasic subtype: 3.57 (1.08–11.8) and albumin < 25 g/L: 10.28 (1.5–70.7) as significant and independent predictors. Conclusions: Second-line and onward nivolumab is effective against MPM in real life but with less effectiveness in >70 years. Ancillary studies are needed to identify the predictive factors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

8. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.

Author

Cadranel, Jacques, Canellas, Anthony, Matton, Lise, Darrason, Marie, Parrot, Antoine, Naccache, Jean-Marc, Lavolé, Armelle, Ruppert, Anne-Marie, and Fallet, Vincent

Subjects
NON-small-cell lung carcinoma, APOPTOSIS, CANCER chemotherapy, CANCER patients, EPIDEMIOLOGY
Abstract

Immune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely observed (<5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (NSCLC) than in those with other cancers. Likewise, it is more common in those receiving programmed cell death (PD)-1/PD-1 ligand inhibitors rather than cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors alone. The frequency of ICI-P is higher when anti-PD-1 and anti-CTLA-4 are administered concomitantly. Despite the low fatality rate (≈13%), ICI-P is the leading cause of ICI-related deaths. This narrative review focuses on the epidemiology, clinical and radiological presentation and prognosis of ICI-P occurring in patients, especially those with advanced NSCLC. Emphasis is placed on the differences in terms of frequency or clinical picture observed depending on whether the ICI is used as monotherapy or in combination with another ICI or chemotherapy. Other pulmonary complications observed in cancer patients, yet not necessarily immune-related, are reviewed, such as sarcoid-like granulomatosis, tuberculosis or other infections. A proposal for pragmatic management, including differential diagnosis and therapeutic strategies, is presented, based on the ICI-P series reported in the literature and published guidelines. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

9. IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).

Author

Girard, Nicolas, Guisier, Florian, Swalduz, Aurélie, Van Hulst, Sylvie, Pichon, Eric, Lavaud, Pernelle, Greillier, Laurent, Tiotiu, Angelica, Madroszyk, Anne, Bylicki, Olivier, Canellas, Anthony, Belmont, Laure, Zysman, Maeva, Hauss, Pierre-Alexandre, Godbert, Benoit, Audigier-Valette, Clarisse, Lebreton, Cléa, Morin, Franck, and Westeel, Virginie

Published
2023
Full Text
View/download PDF

10. Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study.

Author

Benderra, Marc-Antoine, Aparicio, Ainhoa, Leblanc, Judith, Wassermann, Demian, Kempf, Emmanuelle, Galula, Gilles, Bernaux, Mélodie, Canellas, Anthony, Moreau, Thomas, Bellamine, Ali, Spano, Jean-Philippe, Daniel, Christel, Champ, Julien, Canouï-Poitrine, Florence, and Gligorov, Joseph

Subjects
MORTALITY risk factors, RESEARCH, INTENSIVE care units, C-reactive protein, COVID-19, CONFIDENCE intervals, AGE distribution, INFLAMMATION, MULTIVARIATE analysis, MEDICAL cooperation, LUNG tumors, CANCER patients, HOSPITAL mortality, RISK assessment, SEX distribution, BRAIN tumors, SYMPTOMS, DESCRIPTIVE statistics, CANCER patient medical care, LONGITUDINAL method, COMORBIDITY, PROPORTIONAL hazards models, DISEASE complications
Abstract

Simple Summary: COVID-19 may be more frequent and more severe in cancer patients than in other individuals. Our aims were to assess the rate of COVID-19 in hospitalized cancer patients, to describe their demographic characteristics, clinical features and care trajectories, and to assess the mortality rate. A total of 1148 hospitalized patients were included. The mortality rate was 33%. In multivariate analysis, mortality-related factors were male sex, advanced age, more than two comorbidities, C-reactive protein >20 ng/mL, primary brain tumors and lung cancer. Risk of dying was lower among patients with metabolic comorbidities. Background: COVID-19 may be more frequent and more severe in cancer patients than in other individuals. Our aims were to assess the rate of COVID-19 in hospitalized cancer patients, to describe their demographic characteristics, clinical features and care trajectories, and to assess the mortality rate. Methods: This multicenter cohort study was based on the Electronic Health Records of the Assistance Publique-Hôpitaux de Paris (AP-HP). Cancer patients with a diagnosis of COVID-19 between 3 March and 19 May 2020 were included. Main outcome was all-cause mortality within 30 days of COVID-19 diagnosis. Results: A total of 29,141 cancer patients were identified and 7791 (27%) were tested for SARS-CoV-2. Of these, 1359 (17%) were COVID-19-positive and 1148 (84%) were hospitalized; 217 (19%) were admitted to an intensive care unit. The mortality rate was 33% (383 deaths). In multivariate analysis, mortality-related factors were male sex (aHR = 1.39 [95% CI: 1.07–1.81]), advanced age (78–86 y: aHR = 2.83 [95% CI: 1.78–4.51] vs. <66 y; 86–103 y: aHR = 2.61 [95% CI: 1.56–4.35] vs. <66 y), more than two comorbidities (aHR = 2.32 [95% CI: 1.41–3.83]) and C-reactive protein >20 ng/mL (aHR = 2.20 [95% CI: 1.70–2.86]). Primary brains tumors (aHR = 2.19 [95% CI: 1.08–4.44]) and lung cancer (aHR = 1.66 [95% CI: 1.02–2.70]) were associated with higher mortality. Risk of dying was lower among patients with metabolic comorbidities (aHR = 0.65 [95% CI: 0.50–0.84]). Conclusions: In a hospital-based setting, cancer patients with COVID-19 had a high mortality rate. This mortality was mainly driven by age, sex, number of comorbidities and presence of inflammation. This is the first cohort of cancer patients in which metabolic comorbidities were associated with a better outcome. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results